YOUR #1 ANABOLIC STEROIDS SHOP IN THE US - STEROIDS FOR SALE

Cart

Your Cart is Empty

Back To Shop

Oxymethalone 50mg 60 tablets – Watson Anabolic Steroid USA

$103.00

Formula:

Each tablet contains: Oxymetholone 50 mg.

Excipients q.s.p. compressed.

60 pills

Oxymethalone 50mg 60 tablets – Watson Anabolic Steroid USA

 

Oxymethalone properties:

 
Oxymetholone, a powerful anabolic androgenic drug. It is indicated in the treatment of anemia caused by the deficient production of red blood cells. Oxymetholone enhances erythropoietin production in patients with anemia due to bone marrow deficiency and often stimulates erythropoiesis in anemia due to deficiency of erythrocyte production.

Indications:

Oxymetholone (50 mg.) is indicated in the treatment of anemia caused by deficient production of erythrocytes. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis, and anemias due to the administration of myeltoxic substances often respond to treatment. The administration of Oxymetholone (50 mg) should not exclude other supportive measures, such as: blood transfusions, correction of iron, folic acid, vitamin B12 and Pyridoxine, antibacterial therapy and the appropriate use of corticosteroids.

Contraindications:

Before applying the therapy, the doctor must analyze the risks that are run against the needs of the patient. Anabolic agents are generally contraindicated in the following situations:

1. Prostate or breast carcinoma in male patients.

2. Breast carcinoma in female patients with hypercalcemia; anabolic androgenic steroids can stimulate osteolytic bone resorption.

3. Pregnancy: Oxymetholone may be harmful to the fetus. If the patient becomes pregnant while using the drug, she should be informed of the potential danger to the fetus.

1. Hypersensitivity to the drug.

2. Severe hepatic insufficiency.

3. Lactation: It is not known whether anabolic steroids are excreted in breast milk. Due to the potential risk of adverse reactions in nursing infants with breast milk containing anabolic steroids, women taking Oxymetholone should not breast feed.

Cautions and Warnings:

1. Hepatoxicity: Jaundice is common at the prescribed dose. Clinical jaundice may be painless. It may also be associated with acute hepatic enlargement and right upper quadrant pain, which may lead to the misleading assumption of acute bile duct obstruction (requiring surgery). Drug-induced jaundice is usually reversible when the medication is discontinued. Continuous therapy may be associated with hepatic coma and death. Due to the hepatotoxicity associated with the administration of oxymetholone, periodic liver function tests are recommended. Hepatocellular carcinoma and peliosis hepatis (a rare condition of poorly defined etiology) have been observed in patients with congenital and acquired aplastic anemia treated with oxymetholone and other androgens for prolonged periods. In some cases, upon discontinuation of the drug, regression of liver lesions has been observed.

2. Virilization: Virilization can occur in women. Amenorrhea usually appears in adult women, even in the presence of thrombocytopenia. Concomitant administration of large doses of progestagen agents for the control of amenorrhea is not recommended.

3. Iron deficiency: the development of anemia manifested by low serum iron level, and a percentage decrease in transferrin saturation has been observed in patients treated with Oxymetholone. Periodic determination of serum iron and iron conjugation capacity is recommended. If iron deficiency is confirmed, it should be adequately treated with an iron supplement.

4. Leukemia has been observed in patients with aplastic anemia treated with Oxymetholone. The responsibility of Oxymetholone is not yet clear, because malignant transformation has been observed in blood dyscracias and leukemias have been observed in patients with aplastic anemia not treated with Oxymetholone.

5. It is necessary to administer this drug with caution to patients with cardiac, renal or hepatic complaints. Edema, with or without congestive heart failure, may occasionally occur. Concomitant administration with corticosteroids or ACTM may contribute to edema: this is generally controllable, with appropriate diuretic and/or digitalis therapies.

6. Hypercalcemia may develop, both spontaneously and as a result of hormonal therapy, in women with disseminated carcinomas of the breast due to stimulation of osteolysis. If this occurs during use of the drug, use should be discontinued.

7. Anabolic steroids may increase sensitivity to anticoagulants. It may be necessary to decrease the dose of anticoagulants in order to maintain prothrombin at a desirable level.

8. Anabolic steroids have been shown to alter glucose tolerance tests. Diabetics should be carefully observed and insulin or oral hypoglycemic doses adjusted.

9. Anabolic steroids should be used with caution in patients with benign prostatic hypertrophy. In geriatric male patients treated with anabolic androgenic steroids, the risk of developing prostate hypertrophy and prostatic carcinoma may be increased.

10. Alterations in blood lipids, which are known to be associated with an increased risk of arteriosclerosis, have been observed in patients treated with anabolic steroids androgens. These alterations include decreased high-density lipoprotein and sometimes increased low-density lipoprotein. The alterations can be accentuated and have a serious impact on the risk of atherosclerosis and coronary artery disease.

11. Anabolic/androgenic steroids should be used with great caution in children. Anabolic agents may accelerate epiphyseal maturation and more rapidly than linear growth in children, and the effect may persist for 6 months after discontinuation of medication. Therefore, therapy should be monitored by radiographic studies at 6-month intervals, in order to avoid the risk of compromising adult height.

12. Due to serious side effects, anabolic steroids should not be used to stimulate athletic conditions.

Adverse reactions:

1. Hepatotoxicity is one of the adverse reactions most associated with anabolic steroid therapy. The reversible increase in bromosulfalein retention may occur early and appears to be directly dose related. An increase in serum bilirubin, with or without an increase in alkaline phosphatase transaminase (ALT and ALT), indicates a greater degree of excretory dysfunction. The histologic picture is that of intrahepatic cholestasis, with little or no cell injury.

2. Virilization is the most common undesirable effect associated with the use of anabolic steroids. Acne may appear frequently. In pre-pubertal boys, penis enlargement and increased erections, hirsutism, and increased skin pigmentation may also occur. In young post-pubertal males, testicular function is inhibited with oligospermia, seminal volume is decreased, libido is altered and there is impotence. Testicular atrophy may occur. Chronic priapism, male pattern hair loss, epididymitis, and bladder irritability have been reported. Hirsutism, deepening of the voice, clitoral enlargement (which may be irreversible even after discontinuation of medication), altered libido, and menstrual irregularities may occur in women. The use of estrogens in combination with androgens does not prevent virilization in women.

3. Other adverse reactions associated with anabolic androgenic therapy include: nausea, excitement, insomnia, chills, premature closure of the epiphysis in children, vomiting and diarrhea.

4. There are alterations in the thyroid function test: a decrease in PBI, in the conjugation capacity of thyroxine to fix radioactive iodine and an increase in the fixation of T3 by erythrocytes may occur. Free thyroxine is normal. Test abnormalities generally persist for two to three weeks after discontinuation of medication. The excretion of 17-ketosteroids is also reduced.

Posology:

The recommended dose in children and adults is 1 to 5 mg./Kg. of body weight per day. The usual effective dose is 1 to 2 mg/kg/day, but higher doses may be necessary and dosage must be individualized. The response is not always immediate and a minimum therapeutic test must be carried out in 3 to 6 months. After remission, patients can be kept off the drug and others kept on lower daily doses, continuous therapy is generally necessary for patients with congenital aplastic anemia.

Use Restrictions:

Hypersensitivity to the drug. Patients with aplastic anemia. Pregnancy. Lactation. Liver failure.

Buy Oxymetholone online USA.

Cart

Your Cart is Empty

Back To Shop